open access

Vol 3, No 2 (2007)
Review paper
Published online: 2007-03-14
Get Citation

Advances in diagnosis and treatment of plasmocytoma

Anna Dmoszyńska
Onkol. Prak. Klin 2007;3(2):70-77.

open access

Vol 3, No 2 (2007)
REVIEW ARTICLES
Published online: 2007-03-14

Abstract

Plasmocytoma (multiple myeloma) is characterised by monoclonal proliferation of plasma cells which are producing monoclonal immunoglobulin (M protein). Plasma cell tumor occurrence gives it the second place among hematological tumors. The disease develops in many stages. In the first stage the cells B becomes immortal due to chromosomes translocation in the immunoglobuline heavy chain locus. The time from the first incident to symptomatic disease lasts long and takes 20-30 years, so the average age of multiple myeloma detection is 65.
The most important risk factors are the levels of beta2 microglobulines and albumines, on which the prognostic classification is based.

Abstract

Plasmocytoma (multiple myeloma) is characterised by monoclonal proliferation of plasma cells which are producing monoclonal immunoglobulin (M protein). Plasma cell tumor occurrence gives it the second place among hematological tumors. The disease develops in many stages. In the first stage the cells B becomes immortal due to chromosomes translocation in the immunoglobuline heavy chain locus. The time from the first incident to symptomatic disease lasts long and takes 20-30 years, so the average age of multiple myeloma detection is 65.
The most important risk factors are the levels of beta2 microglobulines and albumines, on which the prognostic classification is based.
Get Citation

Keywords

multiple myeloma; thalidomide; lenalidomide; bortezomib; chemotherapy; clinical studies

About this article
Title

Advances in diagnosis and treatment of plasmocytoma

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 2 (2007)

Article type

Review paper

Pages

70-77

Published online

2007-03-14

Bibliographic record

Onkol. Prak. Klin 2007;3(2):70-77.

Keywords

multiple myeloma
thalidomide
lenalidomide
bortezomib
chemotherapy
clinical studies

Authors

Anna Dmoszyńska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl